La substitution hormonale et ses dérivés dans la prévention et le traitement de l'ostéoporose [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis]

Détails

ID Serval
serval:BIB_8B1C8A3BF7D0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
La substitution hormonale et ses dérivés dans la prévention et le traitement de l'ostéoporose [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis]
Périodique
Revue médicale de la Suisse romande
Auteur(s)
Lamy O., Krieg M.A.
ISSN
0035-3655
Statut éditorial
Publié
Date de publication
2002
Volume
122
Numéro
8
Pages
377-81
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review - Publication Status: ppublish
Résumé
Hormone replacement therapy (HRT) is an established approach for the treatment and the prevention of osteoporosis. Many studies with bone mineral density as primary outcome have shown significant efficacy. Observational studies have indicated a significant reduction of hip fracture risk in cohorts of women who maintained HRT therapy. The Women's Health Initiative is the first prospective randomised controlled study which showed a positive effect of HRT in terms of reduction of vertebral and hip fractures risk. Unfortunately, this study has been interrupted after 5.2 years because of the unsupportable increase of risk of cardiovascular disease and breast cancer. Compliance with HRT, however, is typically poor because of the potential side effects and possible increased risk of breast or endometrial cancer. Nevertheless, there is now evidence that lower doses of estrogens in elderly women may prevent bone loss while minimizing the side effects seen with higher doses. Combination therapies using low doses estrogen should probably be reserved for patients who continue to fracture on single therapy. Selective estrogen receptor modulators (SERMs) are very interesting drugs. The goal of these agents is to maximize the beneficial effect of estrogen on bone and to minimize or antagonize the deleterious effects on the breast and endometrium. Raloxifene, approved for the prevention and the treatment of osteoporosis, has been shown to reduce the risks of vertebral fracture in large clinical trials. However, they don't reduce non vertebral fractures. Tibolone is a synthetic steroid that increased bone mineral density at lumbar spine and femoral neck. But no trial has been performed with fractures as end point.
Mots-clé
Aged, Bone Density, Bone Resorption, Dose-Response Relationship, Drug, Estrogen Receptor Modulators, Female, Fractures, Bone, Hormone Replacement Therapy, Humans, Middle Aged, Norpregnenes, Osteoporosis, Randomized Controlled Trials as Topic
Pubmed
Création de la notice
25/01/2008 14:55
Dernière modification de la notice
03/03/2018 19:11
Données d'usage